Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) EBITDA: 2012-2024

Historic EBITDA for Sunshine Biopharma (SBFM) over the last 11 years, with Dec 2024 value amounting to -$6.7 million.

  • Sunshine Biopharma's EBITDA fell 329.12% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.5 million, marking a year-over-year decrease of 52.09%. This contributed to the annual value of -$6.7 million for FY2024, which is 67.69% down from last year.
  • Per Sunshine Biopharma's latest filing, its EBITDA stood at -$6.7 million for FY2024, which was down 67.69% from -$4.0 million recorded in FY2023.
  • In the past 5 years, Sunshine Biopharma's EBITDA registered a high of -$2.8 million during FY2020, and its lowest value of -$26.6 million during FY2022.
  • In the last 3 years, Sunshine Biopharma's EBITDA had a median value of -$6.7 million in 2024 and averaged -$12.4 million.
  • Per our database at Business Quant, Sunshine Biopharma's EBITDA tumbled by 346.03% in 2021 and then spiked by 85.05% in 2023.
  • Over the past 5 years, Sunshine Biopharma's EBITDA (Yearly) stood at -$2.8 million in 2020, then slumped by 346.03% to -$12.4 million in 2021, then plummeted by 113.91% to -$26.6 million in 2022, then soared by 85.05% to -$4.0 million in 2023, then plummeted by 67.69% to -$6.7 million in 2024.